€1.40
+0.00 (+0.00%)
EUR · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where NYXH.BR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 2 observational
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| An Extension Study to Assess the Long-term Safety of the Genio® SystemNCT05939141observationalLong-term safety | — | Not yet recruiting | Device: Genio System | Obstructive Sleep Apnea of Adult | 39 | 2029-07-17 | in 1,063 d | 2025-06-04 |
| Bi-lateral HGN Therapy in Real-World Patients -Post Approval Research InvestigationNCT07331285observationalChange in Apnea Hypopnea Index (AHI4%) | — | Recruiting | Device: This is a single arm study, all consented and eligible subjects will be implanted with the Genio® System 2.1 | Obstructive Sleep Apnea | 229 | Oct 2028 | ≤ 804 d | 2026-06-22 |
| A Post-market Clinical Follow up of the Genio® System for the Treatment of Obstructive Sleep Apnea in AdultsNCT04031040Incidence of device-related Serious Adverse Events (SADEs)Open-label · Treatment | Not applicable | Active, not recruiting | Device: Genio® system therapy | Obstructive Sleep Apnea | 110 | 2026-10-30 | in 72 d | 2026-03-04 |
| Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.NCT05592002Primary Effectiveness EndpointOpen-label · Treatment | Not applicable | Active, not recruiting | Device: Genio System | Sleep Apnea, Obstructive | 124 | Sep 2026 | ≤ 42 d | 2025-09-05 |
| Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea (DREAM)NCT03868618Change in Apnea Hypopnea Index (AHI4%)Open-label · Treatment | Not applicable | Active, not recruiting | Device: Genio™ system | Obstructive Sleep Apnea | 115 | 2024-02-20actual | — | 2026-04-14 |
| BilatEral Hypoglossal Nerve StimulaTion for TreatmEnt of ObstRuctive SLEEP Apnoea With and Without Complete Concentric CollapseNCT03763682Incidence of serious device-related adverse events recorded during the studyOpen-label · Treatment | Not applicable | Terminatedsponsor's stated reason: The study was terminated due to operational challenges impacting protocol execution across sites. | Device: Genio(TM) bilateral hypoglossal nerve stimulation system | Obstructive Sleep Apnea | 42 | 2021-06-28actual | — | 2025-06-06 |
| BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnoea (BLAST OSA)NCT03048604Safety (Incidence of serious device-related adverse events)Open-label · Treatment | Not applicable | Completed | Device: Genio(TM) bilateral hypoglossal nerve stimulation system | Obstructive Sleep Apnea of Adult | 27 | 2018-09-10actual | — | 2021-10-11 |
| Safety and Performance Study of the Nyxoah SAT System for Treating OSANCT02312479Incidence of serious device related adverse eventsOpen-label · Treatment | Not applicable | Terminated | Device: Nyxoah SAT system | Obstructive Sleep Apnea | 6 | Nov 2015actual | — | 2016-09-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19